Dr. Brett Morrison

Dr. Bipasha Mukherjee-Clavin is an Assistant Professor of Neurology in the Johns Hopkins University School of Medicine. She cares for patients with neuromuscular disorders, with a special focus on patients with peripheral neuropathy, immune-mediated neuropathy, and inherited neuropathy (also known as Charcot-Marie-Tooth disease). She sees patients in the Johns Hopkins Peripheral Nerve and multidisciplinary Charcot-Marie-Tooth clinics, and performs electromyography in the Johns Hopkins EMG lab. As a stem cell biology-trained scientist, Dr. Mukherjee-Clavin's research is focused on the use of patient-derived induced pluripotent stem cells to model genetic Schwann cell and peripheral nerve disorders to undercover novel pathways and potential treatments. During her PhD she published one of the first studies of CMT1A using patient derived stem cells (Comparison of three congruent patient-specific cells types for the modelling of a human genetic Schwann-cell disorder. Nature Biomedical Engineering. volume 3, pages 571–582 (2019)). In 2022, she was awarded the Passano award, given to a promising early career physician-scientist in the Johns Hopkins University School of Medicine. Dr. Mukherjee-Clavin completed her undergraduate studies at the University of California, Berkeley. She then completed her MD/PhD degrees, Neurology residency, and clinical Neuromuscular fellowship in the Johns Hopkins University School of Medicine. She joined the Johns Hopkins Neurology faculty in 2022. Dr. Mukherjee is rated as an Experienced provider by MediFind in the treatment of Chronic Polyradiculoneuritis. Her top areas of expertise are Charcot-Marie-Tooth Disease, Guillain-Barre Syndrome, Chronic Polyradiculoneuritis, and Miller-Fisher Syndrome.

Nicholas Maragakis treats patients with motor neuron diseases, such as amyotrophic lateral sclerosis (ALS). This care is coordinated with the Johns Hopkins Center for ALS Specialty Care, a multidisciplinary clinic with expertise in treating patients with ALS and providing support to their caregivers. He serves as medical director of the ALS Clinical Trials Unit, an extension of the multidisciplinary clinic that seeks to facilitate opportunities for patients with ALS to participate in clinical trials that could advance the treatment of this disease. Dr. Maragakis is interested in the basic science of understanding neurodegenerative diseases, as well as the translational potential of therapeutic compounds developed in the laboratory. His fundamental research interest is in using stem cells — more specifically, stem cell-derived motor neurons and glia — for understanding the development and propagation of ALS. His laboratory has been involved in creating and characterizing lines of stem cells from patients with ALS using induced pluripotent stem cell (iPSC) methodologies. The laboratory has a large library of iPSCs from patients with familial ALS and from patients with sporadic ALS. The utilization of this library of iPSCs has facilitated the development of a spinal cord-specific iPSC-astrocyte/motor neuron co-culture system, which has been leveraged for the development of assays that can be used for both the basic understanding of ALS astrocyte and motor neuron biology as well as, eventually, drug screening for ALS therapeutics. His laboratory has taken its long-standing interests in astrocyte biology, as it relates to ALS, to develop a program that investigates astrocyte-specific mechanisms as contributors to the progression (both temporally and anatomically) of disease in ALS. In this vein, there is an interest in astrocytic glutamate transporters and, more recently, astrocyte hemichannels and gap junctions. Dr. Maragakis is rated as an Elite provider by MediFind in the treatment of Chronic Polyradiculoneuritis. His top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, 15q11.2 Microdeletion, and Spinal Muscular Atrophy (SMA).